Buy Carfilnat : Carfilzomib 60 mg Injection Online

Description

1. Active Substance:

• Carfilzomib: Carfilnat contains carfilzomib as its active pharmaceutical ingredient. Carfilzomib is a proteasome inhibitor used in the treatment of multiple myeloma, a type of cancer that affects plasma cells in the bone marrow. Carfilzomib works by inhibiting the activity of proteasomes, which are protein complexes responsible for degrading unwanted or damaged proteins within cells. By blocking proteasome function, carfilzomib helps to induce cell death in cancerous plasma cells.

2. Indications:

• Multiple Myeloma: Carfilnat is indicated for the treatment of multiple myeloma in patients who have received at least one prior therapy. It is used as part of a combination regimen with other anti-cancer medications.
• Relapsed or Refractory Disease: Carfilzomib is particularly useful in the treatment of relapsed or refractory multiple myeloma, where the disease has returned after initial treatment or has not responded to previous therapies.

3. Dosage and Administration:

• The recommended dosage of Carfilnat is 20 mg/m² administered intravenously over 2 to 10 minutes on two consecutive days each week for three weeks (Days 1, 2, 8, 9, 15, and 16), followed by a 12-day rest period.
• Subsequent cycles consist of treatment on Days 1, 2, 8, 9, followed by a rest period.
• The dosage and schedule may vary based on individual patient factors and treatment response, and should be determined by a qualified healthcare professional.

4. Administration:

• Carfilnat is administered by intravenous infusion.
• The injection should be given slowly over 2 to 10 minutes to reduce the risk of infusion reactions.
• It is important to follow proper infusion procedures and precautions to ensure the safe administration of carfilzomib.

5. Effectiveness:

• Carfilnat has demonstrated efficacy in the treatment of multiple myeloma, particularly in patients who have relapsed or are refractory to other therapies.
• Clinical studies have shown that carfilzomib-based regimens can lead to significant improvements in progression-free survival and overall survival compared to standard treatments.

6. Safety Profile:

• Carfilnat is generally well-tolerated when used as prescribed. Common side effects may include fatigue, nausea, vomiting, diarrhea, fever, and low blood cell counts (anemia, thrombocytopenia, neutropenia).
• Serious side effects such as heart failure, pulmonary hypertension, and infusion reactions may occur and require close monitoring.

7. Contraindications:

• Carfilnat is contraindicated in patients with a known hypersensitivity to carfilzomib or any of the excipients in the formulation.
• It should not be used in patients with severe liver impairment or severe heart failure.

8. Precautions:

• Carfilnat should be used with caution in patients with pre-existing cardiac conditions, pulmonary hypertension, or electrolyte imbalances.
• Close monitoring of cardiac function, blood cell counts, and electrolyte levels is recommended during treatment.

9. Storage:

• Carfilnat should be stored according to the manufacturer’s instructions, typically at controlled room temperature (20°C to 25°C) in its original packaging.
• Protect the vials from light and moisture.
• Store the medication out of reach of children and pets.

Carfilnat, manufactured by Natco Pharma Ltd., represents an important therapeutic option for patients with relapsed or refractory multiple myeloma. Treatment should be initiated and supervised by a qualified oncologist, and patients should be closely monitored for both efficacy and safety throughout the treatment course.